Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

BACKGROUND: Bevacizumab is associated with an increased risk of arterial thromboembolism (ATE), however, its effect on venous thromboembolism (VTE) remains controversial. Scant data exist on factors that increase ATE/VTE risk in prostate cancer patients. We investigated the association of bevacizuma...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer
Autori principali: Patel, Jai N., Jiang, Chen, Hertz, Daniel L., Mulkey, Flora A., Owzar, Kouros, Halabi, Susan, Ratain, Mark J., Friedman, Paula N., Small, Eric J., Carducci, Michael A., Mahoney, John F., Kelley, Michael J., Morris, Michael J., Kelly, William K., McLeod, Howard L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4368497/
https://ncbi.nlm.nih.gov/pubmed/25417775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29169
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi